Piflufolastat F-18 injection drugs (Pylarify) from Lantheus (Notice of Intent to sole source)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH - CC

Contract Value

Not provided

Codes & Classification
Solicitation Number

NOI-27-000004

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
Documents2
The National Institutes of Health Clinical Center (NIH-CC) has issued a presolicitation notice indicating its intent to negotiate a sole source contract with Progenics Pharmaceuticals Inc. for the supply of Piflufolastat F-18 injection drugs (Pylarify), developed and owned by Lantheus Medical Imaging. This procurement is critical to the NIH Clinical Center’s Nuclear Pharmacy (CC NP) department, which compounds and dispenses radiopharmaceuticals for daily, life-saving clinical nuclear medicine procedures. These procedures are essential for optimal patient care and are conducted under strict regulatory oversight by the United States Food and Drug Administration (FDA) and the United States Nuclear Regulatory Commission (US NRC), with only RSO-certified Nuclear Medicine personnel authorized to order these drugs. The scope of this procurement encompasses the acquisition of compounded, patient-ready unit doses of Piflufolastat F-18 from an authorized nuclear pharmacy. The intended outcome is to ensure the continued availability of this highly specialized radiopharmaceutical for both patient care and ongoing research protocols at the NIH Clinical Center. Due to the drug’s radioactive nature and rapid decay, it must be compounded, calibrated, and delivered precisely for each patient, making advance storage impossible and necessitating daily, time-sensitive fulfillment. The requirement is structured as an Indefinite Delivery/Indefinite Quantity (IDIQ) contract, with anticipated quantities ranging from 150 to 230 doses of Pylarify injections, plus four unused dose fees per contract period. The contract will cover a base year (10/01/2026 – 09/30/2027) and includes four option years extending through 09/30/2031. The place of performance is the NIH Clinical Center in Bethesda, Maryland. This procurement will be awarded under GSA Contract #36F79719D0170, with Progenics Pharmaceuticals Inc. as the sole authorized provider in the region, as designated by Lantheus Medical Imaging. The statutory authority for this sole source action is 41 U.S.C. 1901 (a)(1), implemented via FAR 13.106-1 and FAR 8.405-6, based on the unique and highly specialized nature of the supplies required. The NAICS code for this procurement is 325412 (Pharmaceutical Preparation Manufacturing), and the Product Service Code is 6505. Interested parties who believe they can meet the requirements are invited to submit capability statements by email, referencing NOI-000004, to Lu Chang at [email protected] by 10:00 AM EST on September 29, 2026. All responses received by the closing date will be considered, though the Government reserves sole discretion in determining whether to compete the requirement. This notice is not a request for proposal, and the opportunity is posted on SAM.gov due to GSA Ebuy category limitations. Contractors evaluating this opportunity should note the highly specialized nature of the requirement, the regulatory constraints, and the sole source justification, which are expected to remain constant throughout the contract lifecycle. For further information, contractors may refer to the official notice at https://sam.gov/opp/905d5e04b13a42ab9fdffb7382700a5d/view or contact the primary point of contact, Lu Chang, at the NIH Clinical Center.